<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="shortcut icon" href="../figures/favicon.png" type="image/x-icon">
  <title>Prenatal Diagnosis Including Preimplantation Genetic Diagnosis</title>
  <link href="https://cdn.jsdelivr.net/npm/remixicon@2.5.0/fonts/remixicon.css" rel="stylesheet">
  <link rel="stylesheet" href="/style.css">
  <link rel="stylesheet" href="/notes.css">
</head>
<body>
  <input type="checkbox" id="main-navigation-toggle" class="btn btn--close" title="Toggle main navigation" />
  <label for="main-navigation-toggle">
    <span></span>
  </label>
  
  <a href="/index.html">
    <div class="home-navigation">
      M
    </div>
  </a>

  <nav id="main-navigation" class="nav-main">
    <ul class="menu">
      <li class="menu__item">
        <a class="menu__link" href="/index.html">Home</a>
      </li>
      <li class="menu__item">
        <a class="menu__link" href="/about-temp2.html">About</a>
      </li>
      
     
      

      <!-- <li class="menu__item">
        <a class="menu__link" href="#0">Projects</a>
        <ul class="submenu">
          <li class="menu__item">
            <a class="menu__link" href="/404.html">Surgery</a>
          </li>
          <li class="menu__item">
            <a class="menu__link" href="/404.html">Pediatrics</a>
          </li>
        </ul>
      </li> -->
    </ul>
  </nav>
  
  <main class="page-container">
    <!-- <div class="contribute-cta">
      <p>Help make this betterðŸ’œ</p>
      <span><a href="/contribute.html">Contribute here</a> </span>
    </div> -->

    <h1>Prenatal Diagnosis Including Preimplantation Genetic Diagnosis</h1>
  
    <!-- <div class="author-flex">
      <div class="author-img">
        <img  src="/contributors/vt1.jpeg" alt="">
      </div>
      <div>
        <h2 class="name">Compiled by Victortayo</h2>
        <p class="updated">last updated, Nov 2022</p>
      </div>
    </div> -->

    <article class="notes">
        <a id='top'></a>
    <article>
    <!-- <h2 class='title'>Outline</h2> -->
    <label class="trigger outline">
        <input type="checkbox" class="checkbox checkbox--red" /> Show/hide outline
        <div class="msg">
         <ol>
            <li><a href="#header-1"></a></li>
            <li><a href="#header-2"></a></li>
            <li><a href="#header-3"></a></li>
            <li><a href="#header-4"></a></li>
            <li><a href="#header-5"></a></li>
            <ul>
              <li><a href="#heading-5-1"></a></li>
              <li><a href="#heading-5-2"></a></li>
              <li><a href="#heading-5-3"></a></li>
              <li><a href="#heading-5-4"></a></li>
              <li><a href="#heading-5-5"></a></li>
              <li><a href="#heading-5-6"></a></li>
          </ul>
            <li><a href="#header-6"></a></li>
            <li><a href="#header-7"></a></li>
         </ol>
        </div>
      </label>

      <section id='header-1'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-1'>Introduction</a>
          </h2>
        </header>
        <div class='body'>
            <p><span class="special-text">Screening</span> is the process of identifying otherwise healthy individuals who may not be otherwise aware that they are at an increased risk of a disease or condition.</p>
            <p><span class="special-text">Prenatal Screening (PNS)</span> is the process of identifying fetuses who are at an increased risk of a disease or a condition by the systematic application of a test to pregnant women in order to identify the fetus who is at sufficient risk of a specific disorder and so will benefit from further investigation.</p>
            <p><span class="special-text">Prenatal diagnosis (PND)</span> is intended to identify or confirm an affected individual </p>
            <p>It is used for detection of anomalies in the fetus before birth. These anomalies may be  </p>
            <ul>
                <li>Genetic/chromosomal anomalies </li>
                <li>Structural defect </li>
                <li>Combination of both</li>
            </ul>
            <p>Prenatal screening and PND is mainly offered for chromosomal disorders and genetic defects </p>
            <p><span class="special-text">PNS</span>: only identifies the fetus at high risk of a condition. Intended to identify populations who have an increased risk for a specific disorder, and for whom diagnostic testing may be warranted.  </p>
            <p><span class="special-text">PND</span>: makes a definitive diagnosis of that condition in the fetus </p>
            <p>Having a positive or high risk screening result does not mean that a fetus will be affected</p>

            <h4><span class="special-text-4">Why offer prenatal screening and PND?</span></h4>
            <p> All pregnant women are at risk of carrying a fetus with a genetic abnormality </p>
            <p> Frequency of inherited malformations and genetic disorders in the newborn is 3% </p>
            <p> Incidence of major abnormality at birth is 2-3% </p>
            <p> 95% of chromosomal anomalies are caused by trisomies 21, 18, 13 (majority T21) </p>
            <p> Routine in some Countries: e.g. Down syndrome screening, anomaly scan in UK, US</p>
            <p>Background risk of chromosomal abnormalities and genetic defects depends on maternal age and the gestational age. The riskâ€” </p>
            <ul>
                <li>Increases with maternal age  </li>
                <li>Reduces with gestational age </li>
            </ul>
            <p>Frequency is higher among abortuses because most serious malformations and genetic disorders result in spontaneous abortion</p>

            <h4><span class="special-text-4">Advantages of PNS and PND </span></h4>
            <p> Enables provision of information to affected women so they can make an informed choice about their babyâ€™s health </p>
            <p> Helps health care provider manage pregnancies better; holistic approach; family centered care </p>
            <p>Provides reassurance/removes anxiety if results are normal   </p>
            <p>If results are abnormal, enables planning. Choice of </p>
            <ul>
                <li>Continuation with pregnancy or termination</li>
                <li>Prenatal treatment</li>
                <li>Planning for the birth of an affected child </li>
            </ul>

            <figure>
                <img src="" alt="">
                <figcaption> </figcaption>
            </figure>

            <p>PNS and PND Can be for </p>
            <ul>
                <li>Chromosomal diseases </li>
                <ul>
                    <li>Trisomy 21, 18, 13 </li>
                </ul>
                <li> Non-chromosomal diseases </li>
                <ul>
                    <li>Single gene disorders e.g., SCD, thalassemia Fetal defects </li>
                    <li>Pre-eclampsia </li>
                    <li>GDM </li>
                    <li>PTB</li>
                </ul>
            </ul>
            <h4><span class="special-text-4b">Screening test</span></h4>
            <ul>
                <li>Cheap and safe tests suitable for whole population</li>
                <li>Selects a subgroup for diagnostic testing</li>
                <li>Sensitivity and positive predictive value is important</li>
            </ul>

            <h4><span class="special-text-4b">Diagnostic tests</span></h4>
            <ul>
                <li>Have a high degree of accuracy</li>
                <li>E.g. amniocentesis for chromosomal abnormalities</li>
                <li>May be invasive, carry risk and are expensive</li>
            </ul>
            <p>Ultrasound can be used for both screening and diagnosis</p>

        </div>

      </section>

      <section id='header-2'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-2'>Prenatal screening</a>
          </h2>
        </header>
        <div class='body'>
            <p></p>
            <p></p>
          <section id='heading-2-1'>
            <header>
              <h3>
                <a aria-hidden href='#heading-2-1'>Measures of the performance of a test </a>
              </h3>
            </header>
            <div class='body'>
               <p><span class="special-text">Detection rate (DR)</span>: the proportion of individuals with a particular condition who test positive for that condition </p>
               <p><span class="special-text">True positive</span>: affected (sick) people correctly identified as affected </p>
               <p><span class="special-text">False positive</span>: unaffected (healthy) person incorrectly identified as affected (sick) </p>
               <p><span class="special-text">True negative</span>: unaffected individuals correctly identified as unaffected </p>
               <p><span class="special-text">False negative</span>: affected individual incorrectly identified as unaffected</p>
               <p><span class="special-text">Sensitivity</span>: ability of a test to correctly identify those with the disease i.e. true positive rate e.g. if 100 people known to have a disease are tested and 45 test positive, it means the sensitivity of the test is 45%. Proportion of actual positives who are correctly identified </p>
               <p><span class="special-text">Specificity</span>: ability of a test to correctly identify those without the disease i.e. True negative rate </p>
               <p><span class="special-text">Positive predictive value</span>: probability that subjects with a positive screening test truly have the disease </p>
               <p><span class="special-text">Negative predictive value</span>: probability that subjects with a negative screening test truly donâ€™t have the disease</p>
               <p>Perfect test should be 100% sensitive (all affected individuals are identified) and 100% specific (no healthy individual is identified as affected)</p>
            </div>
          </section>

          <section id='heading-2-2'>
            <header>
              <h3>
                <a aria-hidden href='#heading-2-2'>Conditions that may benefit from PNS </a>
              </h3>
            </header>
            <div class='body'>
               <p>Chromosomal disorders e.g. T21, 18, 13  </p>
               <p> Neural tube defects </p>
               <p> Genetic disorders e.g. SCD, thalassemia </p>
               <p> Fetal structural anomalies </p>
               <p> Others  </p>
               <ul>
                <li>Preterm birthâ€” using cervical length, fetal fibronectin </li>
                <li>Screening for hemolytic disease of the newborn (rhesus isoimmunization) </li>
                <li>Pre-eclampsiaâ€” using maternal history, mean arterial pressure at 11-13 weeks, uterine artery doppler at 11-13 weeks, biomarkers e.g. pregnancy associated plasma protein A (PAPP-A) </li>
                <li>Gestational DMâ€” maternal BMI, race,  </li>
                <li>Screening for potential neonatal infection e.g. hepatitis B, HIV, syphilis</li>
               </ul>
               <p> PNS is usually offered before PND because of the risk of miscarriage with invasive testing</p>
            </div>
          </section>

          <section id='heading-2-3'>
            <header>
              <h3>
                <a aria-hidden href='#heading-2-3'>Indications for cytogenetic studies (amniocentesis, CVS, FBS) </a>
              </h3>
            </header>
            <div class='body'>
               <p> Advanced maternal age above 35 years </p>
               <ul>
                <li>No unequivocal explanation for the relationship between aneuploidy and advanced maternal age; several theories viz: </li>
                <li>With advancing maternal age, there is decreasing maternal selection against chromosomally abnormal conceptuses. </li>
                <li>Chiasmata between homologous chromosomes decrease in aging oocytes, leading to nondisjunction and chromosomally abnormal ova.  </li>
                <li>Decline in the oocyte pool, or in the number of maturing oocytes per cycle, that accounts for the increase in trisomies with advancing maternal age. </li>
                <li>Risk of trisomy 21 is 1:385 at 35-years, 1:137 at 39 years of age, and 1:30 at 45 years of age.</li>
                <li>Trisomy 13, trisomy 18, 47XXX, and 47XXY also show an increased mean maternal age. </li>
                <li>United States authorities believe that prenatal diagnosis should be offered, as an  alternative to screening, to all women who will be 35 years of age or older when their  infant is born</li>
               </ul>
               <p> Maternal high risk screening score </p>
               <p> Previous child with chromosomal abnormality </p>
               <p> Parental translocation, inversion, or aneuploidy </p>
               <p> Fetuses with intrauterine growth retardation  </p>
               <p> Fetuses with anomalies on ultrasound examination. </p>
               <ul>
                <li>Trisomic fetuses, especially fetuses with trisomy 13 or 18, often show IUGR </li>
                <li>Gross anomalies also frequently can be visualized in fetuses with chromosomal abnormalities </li>
               </ul>
               <p>Antenatal chromosomal studies are appropriate if an abnormal fetus is detected on ultrasound examination. </p>
               <p>Certain biometric findings (e.g., short femur, short humerus, pyelectasis, thickened nuchal fold, nuchal translucency, echogenic bowel, absent nasal bone) are indicative of an increased risk of fetal Down syndrome.</p>

               <h4><span class="special-text-4">Potential indications for cytogenetic studies </span></h4>
               <p> Advanced paternal age </p>
               <p> Previous unexplained stillbirth </p>
               <p> Previous spontaneous miscarriage </p>
               <p> Exposure to radiation or chemotherapeutic agent </p>
               <p>Assisted reproduction; male factor infertility </p>
               <ul>
                <li>Some men with severe oligospermia and nonobstructive  azoospermia have microdeletions of the Y chromosome which  will be transmitted to their male offspring if conception occurs,  either naturally or via IVF/ICSI </li>
                <li>Children born after IVF or ICSI have an increased rate of autosomal and sex chromosome anomalies (1â€“3%)</li>
               </ul>

               <h4><span class="special-text-4">Methods of prenatal screening </span></h4>
               <ul>
                <li> Serum tests </li>
                <li> Ultrasound </li>
                <li> Combination of both</li>
               </ul>

               <h4><span class="special-text-4">Routine prenatal screening </span></h4>
               <ul>
                <li> Offered to all women </li>
                <li> Women should be fully informed and understand the implications of the test </li>
                <li> Test results should be promptly provided </li>
                <li> Referral for definitive diagnosis may be required in women with positive screen results </li>
                <li> Screening offered depends on local protocols</li>
               </ul>

               <h4><span class="special-text-4">Common chromosomal anomalies</span></h4>
               <h4><span class="special-text-4b">Downâ€™s syndrome </span></h4>
               <ul>
                <li> Chromosomal disorder resulting in extra copy of chromosome 21 </li>
                <li> Affects 1 in 700 babies in US </li>
                <li> Commonest aneuploidy compatible with extra-uterine survival </li>
                <li> Risk increases with advancing maternal age </li>
                <li>95% cases caused by non-dysjunction during cell division </li>
                <li>4% caused by translocation </li>
                <li> 1% caused by mosaicism</li>
               </ul>

               <div class="tips-card">
                <p class="tips-card-subtitle">note</p>
                <h4 class="tips-card-title">
                    Downâ€™s syndrome screening 
                </h4>
                <p class="tips-card-content">
                  <ul>
                    <li> All women are at risk of having a fetus with Downâ€™s syndrome </li>
                    <li> In developed countries, all women are offered screening which identifies women at higher risk of having an affected child </li>
                    <li>Screen positive women are offered a diagnostic test (cytogenetic analysis) which could be an invasive test e.g. amniocentesis, Chorionic Villous Sampling, or a blood test (NIPT)</li>
                    <li>Although risk increases with maternal age, if diagnostic testing is only offered to women above 35, only 30% of affected pregnancies will be identified </li>
                  </ul>
                    
                </p>
              </div>

               <h4><span class="special-text-4b"> Edwardâ€™s syndrome (T18)  </span></h4>
               <ul>
                <li>Mostly results in IUGR, IUFD, NND</li>
                <li>Very rarely does survival to adulthood occur</li>
                <li>1 in 3,000-6,000 live births </li>
               </ul>
               <h4><span class="special-text-4b">Patauâ€™s syndrome: (T13)</span></h4>
               <ul>
                <li>Most infants die within 1st week of life</li>
                <li>Occurs in 1 in 16,000 newborns</li>
               </ul>



            </div>
          </section>

          <section id='heading-2-4'>
            <header>
              <h3>
                <a aria-hidden href='#heading-2-4'>Screening for chromosomal anomalies </a>
              </h3>
            </header>
            <div class='body'>
               <p>Using certain markers of Aneuploidy </p>
               <p>Ultrasound markers </p>
               <ul>
                <li>Nuchal Translucency (NT) >3.5mm </li>
                <li>Absence of Nasal bone </li>
                <li>Soft markers e.g. echogenic foci in the heart, echogenic bowel </li>
               </ul>
               <p>Serum markers </p>
               <ul>
                <li>Alpha Fetoprotein (AFP) </li>
                <li>Human Chorionic Gonadotropin (hCG) </li>
                <li>Unconjugated nostril (uE3) </li>
                <li>Pregnancy associated plasma protein A (PAPP-A)</li>
               </ul>

               <h4><span class="special-text-4">When do we screen for chromosomal defects? </span></h4>
               <ul>
                <li>First trimester </li>
                <li>Second trimester </li>
               </ul>
               <h4><span class="special-text-4b">1st trimester USS markers  </span></h4>
               <ul>
                <li> Raised Nuchal Translucency (NT) > 3.5mmâ€” increased risk of Downâ€™s, Turner, heart defects </li>
                <li> Absent nasal boneâ€”T21 </li>
                <li> Hypoplastic maxillaâ€”T21 </li>
                <li> Omphalocoeleâ€”T18 </li>
                <li> Single umbilical arteryâ€”T18</li>
               </ul>

               <div class="tips-card">
                <p class="tips-card-subtitle">note</p>
                <h4 class="tips-card-title">
                  Nuchal translucency 
                </h4>
                <p class="tips-card-content">
                  <ul>
                    <li>Single most useful marker of aneuploidy </li>
                    <li>Chances of fetal abnormality increases as NT increases </li>
                    <li>Measures subcutaneous collection of fluid under babyâ€™s neck using ultrasound </li>
                    <li> Measured in 1st trimester when CRL is 45-84 mm </li>
                    <li>99th centile is 3.5 mm </li>
                    <li> May be increased in </li>
                    <ul>
                        <li>Congenital infection</li>
                        <li>Fetal anemia</li>
                        <li>Chromosomal anomaly e.g. Downâ€™s</li>
                        <li>Structural malformations </li>
                    </ul>
                  </ul>
                </p>
              </div>

              <section id='heading-2-4-1'>
                <header>
                  <h4>
        
                    <a aria-hidden href='#heading-2-4-1'>Maternal serum screening for T21 </a>
                  </h4>
                </header>
                <div class='body'>
                    <p> Detects levels of serum markers: free beta hCG, PAPP-A, AFP, estriol, inhibin </p>
                    <p> May be performed in the first or second trimester  </p>
                    <p>It is a non-invasive method of PNS i.e. no risk to the pregnancy  </p>
                    <p>Aims at identifying women with increased risk of T13, 18, 21   </p>
                    <p>Used in conjunction with USS markers gives detection rate up to 85%</p>

                    <h4><span class="special-text-4b">Betaâ€”hCG </span></h4>
                    <p> hCG produced by placenta </p>
                    <p> In Downâ€™s syndrome,  </p>
                    <ul>
                        <li>Both alpha and beta subunits are increased but free beta subunit is used for screening </li>
                        <li>Placenta is hypersecretory and immature resulting in increased secretion of beta hCG usually commencing at end of 1st trimester and continuing into the 2nd trimester </li>
                        <li>Detection rate for T21 when used alone = 33%</li>
                    </ul>

                    <h4><span class="special-text-4b">PAPP-A </span></h4>
                    <p>Pregnancy associated plasma protein A </p>
                    <p>Concentration is lower in pregnancies with aneuploidy  </p>
                    <p>Detection rate for T21 is 38% when used alone</p>

                    <h4><span class="special-text-4b">Unconjugated estriol (uE3) </span></h4>
                    <p>Produced by the placenta </p>
                    <p>Decreased in Downâ€™s syndrome </p>
                    <p>Also low in IUGR, oligohydramnios</p>
        
                    <h4><span class="special-text-4">Biochemical markers are affected by </span></h4>
                    <ul>
                        <li> Smoking status: smoking can alter the PAPP-A result by up to 20% </li>
                        <li> Maternal weight at sampling: the exact weight on the day the sample is taken is essential for calculating the correct T21 risk. An error of as little as 3kg can have a dramatic effect on the final risk result. </li>
                        <li> Family origins: some biochemical markers like PAPP-A are 60% higher in Afro-Caribbean women, which will bias the results if not adjusted for. </li>
                        <li> Assisted conception: the risk of T21 increases with the mother's but not the father's age. </li>
                    </ul>

                </div>
              </section>
            </div>
          </section>

          <section id='heading-2-5'>
            <header>
              <h3>
                <a aria-hidden href='#heading-2-5'>Various screening modalities </a>
              </h3>
            </header>
            <div class='body'>
                <section id='heading-2-5-1'>
                    <header>
                      <h4>
                        <a aria-hidden href='#heading-2-5-1'>1st trimester screening for aneuploidy (Combined test) </a>
                      </h4>
                    </header>
                    <div class='body'>
                        <p> Determines risk for aneuploidy (commonly Trisomy 21, 18, 13) using a combination of </p>
                        <ul>
                          <li>Maternal age (to determine background risk) </li>
                          <li>Maternal serum screen (free beta hCG + PAPP-A) Nuchal Translucency (NT) </li>
                          <li>Serum markers are independent of NT so combination of both results in increased detection rate  </li>
                        </ul>
                        <p> >90% detection rate for T21 </p>
                        <p> Done at GA of 11 weeks + 2 days to 14 weeks + 1 day (when CRL is 45- 84 mm)</p>
            
                    </div>
                </section>

                <section id='heading-2-5-2'>
                  <header>
                    <h4>
          
                      <a aria-hidden href='#heading-2-5-2'>2nd trimester screening </a>
                    </h4>
                  </header>
                  <div class='body'>
                    <h4><span class="special-text-4">Triple test</span></h4>
                    <ul>
                      <li> E.g. triple test, quadruple test, genetic sonogram </li>
                      <li> Triple test measures alpha fetoprotein (AFP) + hCG + unconjugated estriol (uE3) </li>
                      <li> Performed at 15-20th week in women who did not present early enough to benefit from the 1st trimester screening </li>
                      <li> Serum markers are combined with maternal age, weight, ethnicity and GA to give a risk score </li>
                      <li> Has 69% DR for T21 (Downâ€™s syndrome)</li>
                    </ul>
                    <h4><span class="special-text-4">Quadruple test </span></h4>
                    <ul>
                      <li> For late bookers when NT no longer possible </li>
                      <li>Detection rate is 80% for T21 </li>
                      <li> Inhibin is added to triple test markers i.e. measures AFP + hCG + uE3 + inhibin </li>
                      <li> Performed at 14-20 weeks (ideally, 14-16 weeks)  </li>
                      <li>Has 80% DR for T21</li>
                    </ul>
          
                  </div>
                </section>

                <section id='heading-2-5-3'>
                  <header>
                    <h4>
          
                      <a aria-hidden href='#heading-2-5-3'>Integrated screening </a>
                    </h4>
                  </header>
                  <div class='body'>
                      <p>Combines 1st and 2nd trimester screening into a single risk </p>
                      <p>Gives the highest Down syndrome detection rate of 90- 96% </p>
                      <p>Disadvantage: test results are not available until 2nd trimester tests are complete which might lead to delay in intervention</p>
          
                  </div>
                </section>

                <section id='heading-2-5-4'>
                  <header>
                    <h4>
          
                      <a aria-hidden href='#heading-2-5-4'>Sequential screening </a>
                    </h4>
                  </header>
                  <div class='body'>
                      <p>Results of 1st trimester test is disclosed to the woman  enabling choice of early invasive test for women at high  risk and those at low risk can go ahead with the 2nd trimester tests</p>
                    
          
                  </div>
                </section>
            </div>
          </section>

        </div>
      </section>

      <section id='header-3'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-3'>PND </a>
          </h2>
        </header>
        <div class='body'>
          <p>Detection of anomalies in the fetus before birth/ May be  </p>
          <ul>
            <li>Genetic abnormalities/chromosomal anomalies </li>
            <li>Structural defect </li>
            <li>Combination of both</li>
          </ul>
          <p>Aim is not to generate perfect babies but to help parents learn what they need to know about the health of their unborn child to help them make informed decisions for themselves and their family within the context of their own value system</p>

          <h4><span class="special-text-4b">PND aims at detecting </span></h4>
          <ul>
            <li>Birth defects e.g. NTD, cleft palate, anterior abdominal wall defects </li>
            <li>Chromosomal abnormalities e.g. Downâ€™s syndrome genetic diseases e.g. hamoglobinopathies, cystic fibrosis </li>
            <li>Other conditions that may adversely affect the fetus when it is born</li>
          </ul>

          <h4><span class="special-text-4b">Why offer PND? </span></h4>
          <ul>
            <li>Primary aim of PND: to provide an accurate diagnosis that will allow informed decision making in couples at increased risk of having children with genetic conditions or congenital abnormalities </li>
            <li>To enable early diagnosis and timely treatment in or ex- utero to give parents the option of aborting a fetus with a diagnosed condition (if local abortion laws permit) to enable the parents and healthcare provider to prepare for the birth and care of an affected  child psychologically, socially, financially, medically or for the likelihood of a stillbirth</li>
          </ul>

          <h4><span class="special-text-4b">Who is PND offered to? </span></h4>
          <ul>
            <li> Usually, pregnant women with positive prenatal screening results in other to arrive at a definitive diagnosis </li>
          </ul>

          <section id='heading-3-1'>
            <header>
              <h3>
                <a aria-hidden href='#heading-3-1'>Indications for PND </a>
              </h3>
            </header>
            <div class='body'>
               <p> High risk prenatal screening test result </p>
               <p> Advanced maternal age e.g. screening for Downâ€™s </p>
               <p> Previous child with chromosomal or structural abnormality </p>
               <p> Family history of inherited condition e.g. single gene disorders like SCD, Neurofibromatosis, achondroplasia </p>
               <p> Family history of structural abnormality e.g. Neural Tube Defect (NTD), CHD </p>
               <p> Other risk factors e.g. co-sanguinous marriage, poor obstetric history e.g. recurrent miscarriage, maternal DM, antenatal exposure to illnesses that could cause fetal abnormalities e.g. toxoplasmosis, rubella </p>
               <p> Antenatal exposure to teratogens </p>
               <p> Incidental findings of abnormalities during routine anomaly scan </p>
            </div>
          </section>

          <section id='heading-3-2'>
            <header>
              <h3>
                <a aria-hidden href='#heading-3-2'>Methods of PND </a>
              </h3>
            </header>
            <div class='body'>
               <p>Can be invasive or noninvasive</p>
               
               <h4><span class="special-text-4"> Noninvasive methods </span></h4>
              <ul>
                <li>Fetal visualization e.g. Ultrasound, fetal echo, MRI  </li>
                <li>Maternal serum screening e.g. maternal serum alpha fetoprotein for NTD  </li>
                <li>Noninvasive prenatal testing (NIPT) </li>
              </ul>

              <h4><span class="special-text-4"> Invasive methods </span></h4>
              <ul>
                <li>Fetal visualization e.g. embryoscopy, fetoscopy </li>
                <li>Tissue sampling e.g. amniocentesis, Chorionic villous sampling (CVS), percutaneous umbilical blood sampling (PUBS), skin, muscle or liver biopsy </li>
                <li>Specimens from invasive tests are sent for cytogenetic analysis</li>
              </ul>

              <h4><span class="special-text-4b">Disadvantages of invasive tests </span></h4>
              <ul>
                <li>Risk of mother to child transmission (MTCT) of diseases eg HIV, hepatitis so screen before the test;  </li>
                <li>Risk of sensitization of Rhesus negative mother so give Rh immunoglobulin in Rh -women </li>
                <li>Risk of pregnancy loss </li>
              </ul>

              <section id='heading-3-2-1'>
                <header>
                  <h4>
        
                    <a aria-hidden href='#heading-3-2-1'>Ultrasound  </a>
                  </h4>
                </header>
                <div class='body'>
                    <p> May be used in isolation or as an adjunct for invasive testing (e.g. amniocentesis and CVS) </p>
                    <p> Abnormalities may be picked up in the 1st trimester  </p>
                    <p>Anomaly scan is usually offered at 20-22 weeks  </p>
                    <p>Useful in detecting structural abnormalities e.g. </p>
                    <ul>
                      <li>Neural tube defects: anencephaly, meningocoele  </li>
                      <li>Anterior abdominal wall defect </li>
                      <li>Heart defects </li>
                      <li>Multiple defects</li>
                    </ul>
        
                </div>
              </section>

              <section id='heading-3-2-2'>
                <header>
                  <h4>
        
                    <a aria-hidden href='#heading-3-2-2'>Amniocentesis </a>
                  </h4>
                </header>
                <div class='body'>
                    <p> Commonest invasive procedure </p>
                    <p> Involves insertion of a needle into the amniotic cavity and aspiration of amniotic fluid which is sent for analysis </p>
                    <p> Usually performed at 15-18 weeks gestation though may be done later  </p>
                    <p>Obtained sample is sent for cytogenetic analysis</p>

                    <h4><span class="special-text-4"Complications of Amniocentesis ></span></h4>
                    <ul>
                      <li> Miscarriage; 1% </li>
                      <li> Intra-amniotic bleeding </li>
                      <li> Abruptio placentae </li>
                      <li> Rupture of membranes </li>
                      <li> Infection </li>
                      <li> Long term effects </li>
                      <ul>
                        <li>Fetal lung development </li>
                        <li>Limb deformities</li>
                      </ul>
                    </ul>
        
                </div>
              </section>

              <section id='heading-3-2-3'>
                <header>
                  <h4>
        
                    <a aria-hidden href='#heading-3-2-3'>Chorionic villous sampling </a>
                  </h4>
                </header>
                <div class='body'>
                    <p> Needle introduced to aspirate placental tissue; </p>
                    <p>Usually transabdominal; transvaginal if posterior placenta, retroverted uterus  </p>
                    <p> Can be performed earlier than amniocentesis; usually 11-14 weeks</p>

                    <h4><span class="special-text-4">Complications of CVS </span></h4>
                  <ul>
                    <li> Miscarriage; 1-2%  </li>
                    <li> Injury to surrounding structures </li>
                    <li> Confined placental mosaicism</li>
                  </ul>
        
                </div>
              </section>

              <section id='heading-3-2-4'>
                <header>
                  <h4>
                    <a aria-hidden href='#heading-3-2-4'>Embryoscopy  </a>
                  </h4>
                </header>
                <div class='body'>
                    <p>1st trimester procedure </p>
                    <p>Rigid endoscope inserted via cervix under USS guidance to visualize structural malformations</p>
        
                </div>
              </section>

              <section id='heading-3-2-5'>
                <header>
                  <h4>
        
                    <a aria-hidden href='#heading-3-2-5'>Fetoscopy </a>
                  </h4>
                </header>
                <div class='body'>
                    <p> Endoscopic visualisation of the fetus </p>
                    <p> Performed in 2nd trimester >16 weeks (usually at 18-20 weeks) </p>
                    <p> Endoscope inserted into amniotic cavity through an anterior abdominal wall incision;  </p>
                    <p> 3-5 % miscarriage rate </p>
                    <p> Enables  </p>
                    <ul>
                      <li>Detection of structural abnormalities </li>
                      <li>Fetal blood sampling for haemoglobinopathies </li>
                      <li>Fetal biopsy; skin, liver </li>
                      <li>Fetal surgery; ablation of anastomoses in ttts, selective feticide, division of amniotic bands</li>
                    </ul>
        
                </div>
              </section>

              <section id='heading-3-2-6'>
                <header>
                  <h4>
        
                    <a aria-hidden href='#heading-3-2-6'>Cordoscentesis/percutaneous umbilical blood sampling </a>
                  </h4>
                </header>
                <div class='body'>
                    <p> Ultrasound guided procedure to obtain fetal blood from umbilical cord </p>
                    <p> Also used for in-utero transfusion e.g. in anemia from Rhesus iso-immunization</p>
        
                </div>
              </section>

              <section id='heading-3-2-7'>
                <header>
                  <h4>
        
                    <a aria-hidden href='#heading-3-2-7'>Noninvasive Prenatal Diagnosis (NIPD) </a>
                  </h4>
                </header>
                <div class='body'>
                    <p> Detects fetal DNA fragments present in maternal plasma during pregnancy i.e. cell free DNA most</p>
                    <ul>
                      <li>cfDNA is maternal in originâ€”cell free maternal DNA </li>
                      <li>10-20% is fetal in originâ€¦cell free fetal DNA (cffDNA) </li>
                    </ul>
                    <p> Detectible as early as 6 weeks gestation </p>
                    <p> Can detect fetal sex, chromosomal abnormalities,  </p>
                    <p> Useful in whole genome sequencingâ€” determining the complete DNA sequence of every gene </p>
                    <p> Can detect about 99% of cases of trisomy 21, 97% of trisomy 18, and 92% of trisomy 13, with respective false- positive rates of 0.08%, 0.15%, and 0.2%  </p>

                    <h4><span class="special-text-4b"> Advantages </span></h4>
                    <ul>
                      <li> Safe and easy; no risk to mother or fetus </li>
                      <li> Performed early in gestation, allowing time for decision-making/early pregnancy termination/preparation for affected child</li>
                    </ul>

                    <h4><span class="special-text-4">cffDNA </span></h4>
                    <ul>
                      <li> First detected in maternal blood at 4-5 weeks </li>
                      <li> Cleared from maternal circulation within 1 hour of birth so is specific to the current pregnancy</li>
                    </ul>

                    <h4><span class="special-text-4b">Uses  </span></h4>
                    <ul>
                      <li> Screening for Downâ€™s syndrome </li>
                      <li> Detection of some single gene disorders e.g. achondroplasia, thanatophoric dysplasia, SCD </li>
                      <li> Fetal sex determination </li>
                      <li>Useful in pregnancies at risk of serious X linked conditions e.g. Congenital Adrenal Hyperplasia (CAH), Duchene muscular dystrophy (DMD)</li>
                    </ul>

                    <h4><span class="special-text-4b">Benefits of NIPT/NIPD </span></h4>
                    <ul>
                      <li>Reduced requirement for invasive testing</li>
                      <li>No risk of miscarriage </li>
                      <li> Can be offered earlier than traditional testing</li>
                    </ul>
                    
                    <h4><span class="special-text-4b">Limitations  </span></h4>
                    <ul>
                      <li> In multiple pregnancy, impossible to deternine which fetus the DNA is from </li>
                      <li> Women with high BMI have relatively reduced cffDNA because they have a higher proportion of their own cell free DNA resulting in higher chance of inconclusive result </li>
                      <li> Cost</li>
                    </ul>


        
                </div>
              </section>
            </div>
          </section>

          <section id='heading-3-3'>
            <header>
              <h3>
                <a aria-hidden href='#heading-3-3'>Management options following PND</a>
              </h3>
            </header>
            <div class='body'>
               <p>Continue with the pregnancyâ€” increased risk of having an affected child, IUGR, stillborn, NND</p>
               <p>Termination of pregnancy</p>
               <p>In-utero therapy</p>
               <p>Post-natal treatment</p>
            </div>
          </section>


        </div>
      </section>

      <section id='header-4'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-4'>Ultrasound in PNS/PND  </a>
          </h2>
        </header>
        <div class='body'>
          <p>Typesâ€” 2D, 3D </p>
          <p> Aneuploidy screeningâ€” NT scan </p>
          <p> 1st trimester screening for fetal anomalies </p>
          <p>2nd trimester anomaly scan</p>

          <h4><span class="special-text-4">20-22 weeks scan </span></h4>
          <h4><span class="special-text-4b"> Indications </span></h4>
          <ul>
            <li> Fetal anatomy and growth </li>
            <li> Placenta localization </li>
            <li> Amniotic fluid volume </li>
            <li> Uterine artery dopplers </li>
            <li> Cervical length</li>
          </ul>
          <h4><span class="special-text-4">3D ultrasound </span></h4>
          <p> Useful for diagnoses of certain birth defects e.g. cleft lip  </p>
          <p>More easily understood by parents </p>
          <p> Data can be stored for later evaluation by a specialist can be used to calculate tissue and fluid volumes e.g. lung volume measurements for prediction of pulmonary hypoplasia in CDH</p>

          <div class="tips-card">
            <p class="tips-card-subtitle">note</p>
            <h4 class="tips-card-title">
              Fetal MRI
            </h4>
            <p class="tips-card-content">
              <ul>
                <li>Complementary to ultrasound</li>
                <li>Particularly useful in CNS, thoracic and lung abnormalities e.g. encephalocoele, congenital diaphragmatic hernia</li>
              </ul>
                
            </p>
          </div>

        </div>
      </section>

      <section id='header-5'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-5'>Common Congenital Anomalies</a>
          </h2>
        </header>
        <div class='body'>
          <h4><span class="special-text-4">Anencephaly  </span></h4>
          <p>Partial or complete failure of closure of anterior end of neural tube</p>
          <p>NTD characterized by absence cranial vault and cerebral hemispheres </p>
          <p>Absent skull; exposure of cerebral cortex</p>
          <p>100% DR by Ultrasound. 1st trimester USS diagnosis possible</p>
          <ul>
            <li>Absent cranium </li>
            <li>Brain tissue seen exposed to amniotic cavity </li>
            <li>Prominent eyes and ears</li>
          </ul>
          <p>Lethal; 50% stillborn; remaining die early NND</p>

          <h4><span class="special-text-4">Microcephaly </span></h4>
          <p> May occur in genetic syndromes </p>
          <p>Trisomies </p>
          <p>Congenital infections </p>
          <p> Drugs/alcohol </p>
          <p>Constitutional</p>

          <h4><span class="special-text-4">Encephalocoele</span></h4>
        <p>Skin covered NTD affecting cranium resulting in midline mass overlying skull defect</p>
        <p>75% occipital; 12% frontal, 13% parietal</p>
        <p>Mass may be filled with fluid, brain or both</p>

        <h4><span class="special-text-4">Spina Bifida</span></h4>
        <p>Failure of vertebral arches to close prior to 6th week due to failure of normal neural ectoderm development</p>
        <p>Prenatal diagnosis</p>
        <ul>
          <li>Raised MSAFP</li>
          <li>USS</li>
        </ul>

        <div class="tips-card">
          <p class="tips-card-subtitle">note</p>
          <h4 class="tips-card-title">
            Screening for neural tube defects
          </h4>
          <p class="tips-card-content">
            <ul>
              <li>Biochemistry: maternal serum alphafetoprotein at 16-18 weeks</li>
              <li>Amniotic fluid serum alpha fetoprotein</li>
              <li>Ultrasound to detect neural tube defects</li>
            </ul>
          </p>
        </div>


        <h4><span class="special-text-4">Heart defects </span></h4>
        <p> Prenatal detection enables consideration of options  </p>
        <ul>
          <li>PND of genetic abnormality </li>
          <li>Continuing with pregnancy </li>
          <li>Termination if allowed </li>
        </ul>
        <p>Plan delivery; place, timing, neonatal care  </p>
        <p>Counsel regarding risks in subsequent pregnancy</p>

        <h4><span class="special-text-4">GI anomalies e.g. duodenal atresia</span></h4>
        <p>Associated with T21</p>
        <p>Other cardiac, skeletal</p>
        <p>Renal and GI defects may be present</p>

        <h4><span class="special-text-4">Renal genitourinary anomalies</span></h4>
        <p>Various types</p>
        <p>May be minor or major, lethal or non-lethal</p>
        <p>Lethal e.g. bilateral renal agenesis: counsel; offer TOP if allowed</p>
        <p>Non-lethal eg posterior urethral valve; consider in-utero therapy, optimize time and place of delivery</p>

        <h4><span class="special-text-4">Anterior abdominal wall defects</span></h4>
        <h4><span class="special-text-4b">Gastroschisis</span></h4>
        <p>Herniation of bowel, liver and other organs into amniotic cavity</p>
        <p>Not covered by peritoneal membrane</p>
        <p>Typically the hernia is on the right side of a normally inserted umbilical cord</p>

        <h4><span class="special-text-4b">Exomphalos</span></h4>
        <p>Herniation of bowel, liver and other organs into the intact umbilical cord</p>
        <p>Tissues are covered by peritoneal membrane</p>
        <p>Umbilical cord inserts into the hernia</p>


        </div>
      </section>

      <section id='header-6'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-6'>Preimplantation Genetic Diagnosis (PGD)</a>
          </h2>
        </header>
        <div class='body'>
           <p></p>
           <p></p>
           <p></p>
           <p></p>

           <h4><span class="special-text-4">Some ethical dilemmas in PGD</span></h4>
          <p>Late onset disorders or for cancer predisposition,</p>
          <p>BRCA1 and 2 mutation, by 70years, 65% risk of breast cancer, 39% for ovarian in BRCA1; 45% and 11% for BRCA-2 respectively</p>
          <p>Li Fraumeni syndrome (genetic predisposition to cancer later in life; 55% develop cancer by 40 yrs, 90% by 60 yrs)</p>
          <p>Legality or otherwise of transferring an affected embryo (illegal in UK; HFEA act 2008)</p>
          <p>PGD for HLA matching: welfare of present versus future child; harvesting organs, benefits for receiving child versus disadvantages for the future child; what If the treatment fails?</p>
          <p>Informed decision making; non-directive counseling</p>
        </div>
      </section>

      <section id='header-7'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-7'> Prenatal screening and diagnosis of non-chromosomal diseases</a>
          </h2>
        </header>
        <div class='body'>
           <p>RhD alloimmunization</p>
           <p>Pre-eclampsia</p>
           <p>Gestational diabetes</p>
           <p>Fetal growth restriction</p>
           <p>Preterm birth</p>
           <p>Fetal defects</p>

           <h4><span class="special-text-4">RhD isoimmunization</span></h4>
          <p>D antigen: present on surface of RBC of Rh + individual; absent in Rh â€“</p>
          <p>Pathophysiology:</p>
          <ul>
            <li>Feto-maternal exchange of blood may occur during pregnancy, delivery, invasive procedures, miscarriages etc.</li>
            <li>First pregnancy: Rh + cells crossover into Rh - mother, mother produces anti-D antibodies</li>
            <li>Subsequent pregnancy: motherâ€™s antibodies cross the placenta and destroy fetusâ€™s RBC- haemolysis, anemia and its sequelae e.g. CCF, hydrops</li>
            <li>Prevented by giving mother anti-D immunoglobulin (it prevents mother from producing anti D antibodies; ideally given prophylactically at 28 and 34 weeks and following delivery of Rh + infant, invasive procedures etc.</li>
          </ul>
          <p>Cell free fetal DNA or amniotic fluid PCR can be performed for PND of fetal rhesus status so that Rh immunoglobulin is only given if the fetus is actually Rh positive.</p>


        </div>
      </section>

      <section id='header-8'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-8'> Screening for preterm birth (PTB)</a>
          </h2>
        </header>
        <div class='body'>
           <p>A sonographic short cervix diagnosed by transvaginal ultrasound is the most powerful predictor of preterm delivery (50% of women with a cervical length â‰¤15 mm will deliver prior to 32 weeks of gestation).</p>
           <p>Cervical length at 22-24 weeks < 25mm by TVS results in > 6fold increased risk for PTB < 35 weeks</p>
           <p>Randomized clinical trials and systematic reviews have demonstrated that vaginal progesterone reduces significantly the rate of preterm birth by 50% and reduces neonatal morbidity/mortality</p>
           <p>Fetal fibronectin in cervico-vaginal secretions also used to screen for PTB</p>
        </div>
      </section>

      <section id='header-9'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-9'>Conclusion/recap </a>
          </h2>
        </header>
        <div class='body'>
           <p>Various modalities for prenatal screening and prenatal diagnosis</p>
           <p>Allows early decision making regarding pregnancy</p>
           <p>PNS identifies fetus at high risk of a condition, PND identifies fetus with the condition</p>
           <p>PNS and PND commonly offered for chromosomal diseases but may also be offered for genetic diseases (e.g. SCD), fetal defects (e.g. NTD), maternal conditions (e.g. PET, PTB)</p>
           <p>Prenatal screening should be offered to all women depending on local protocol</p>
           <p>Prenatal diagnosis should be offered to women with high risk prenatal screening results or other women with indications for PND</p>
           <p>Ultrasound is beneficial in both screening and diagnosis</p>
           <p>PNS: combined test, triple test, quadruple test</p>
           <p>PND: may require invasive procedures which carry risks of miscarriage</p>
           <p>NIPT enables PND without associated risk of miscarriage</p>
           <p>PGD may be an option</p>
        </div>
      </section>

      </section>

      <div class="contact">
        <hr style="margin: 3rem 0;">

        <!-- <p>Send us a <a href="mailto:obgyn.materia@gmail.com"><span class="special-text-2">mail</span></a> at 
         <br> obgyn.materia@gmail.com.</p>
        <p>Or send your comments, corrections, explanations/clarifications and requests/suggestions to our 
         <br> <a href="" class="special-text-2" style="text-decoration: none;">WhatsApp group</a>.</p> -->
      </div>
    </article>
   </article>
   <div style="height: 300px;"></div>
  </main>

  <footer>
    <div class="footer-container">
        <div>
          <p>obgyn.materia.[beta]</p>
          
        </div>
    </div>
  </footer>
<!------------  SCROLL UP ----------->
<a href="#" class="scrollup" id="scroll-up"> 
  <i class="ri-arrow-up-fill scrollup__icon"></i>
</a>
<script src="/main.js"></script>
</body>
</html>
 
